Animal models of idiosyncratic drug-induced liver injury—Current status

References

• Alvarez-Sanchez R, Montavon F, Hartung T, Pahler A. (2006). Thiazolidinedione bioactivation: A comparison of the bioactivation potentials of troglitazone, rosiglitazone, and pioglitazone using stable isotope-labeled analogues and liquid chromatography tandem mass spectrometry. Chem Res Toxicol 19:1106–1116.
   PubMed Web of Science ®Google Scholar
• Andrade RJ, Robles M, Ulzurrun E, Lucena MI. (2009). Drug-induced liver injury: Insights from genetic studies. Pharmacogenomics 10:1467–1487.
   PubMed Web of Science ®Google Scholar
• Antoine DJ, Williams DP, Park BK. (2008). Understanding the role of reactive metabolites in drug-induced hepatotoxicity: State of the science. Expert Opin Drug Metab Toxicol 4:1415–1427.
   PubMed Web of Science ®Google Scholar
• Antoine DJ, Mercer AE, Williams DP, Park BK. (2009). Mechanism-based bioanalysis and biomarkers for hepatic chemical stress. Xenobiotica 39:565–577.
   PubMed Web of Science ®Google Scholar
• Arbour NC, Lorenz E, Schutte BC, Zabner J, Kline JN, Jones M, Frees K, Watt JL, Schwartz DA. (2000). TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 25:187–191.
   PubMed Web of Science ®Google Scholar
• Bacon JA, Cramer CT, Petrella DK, Sun EL, Ulrich RG. (1996). Potentiation of hypoxic injury in cultured rabbit hepatocytes by the quinoxalinone anxiolytic, panadiplon. Toxicology 108:9–16.
   PubMedGoogle Scholar
• Bauman JN, Kelly JM, Tripathy S, Zhao SX, Lam WW, Kalgutkar AS, Obach RS. (2009). Can in vitro metabolism-dependent covalent binding data distinguish hepatotoxic from nonhepatotoxic drugs? An analysis using human hepatocytes and liver S-9 fraction. Chem Res Toxicol 22:332–340.
   PubMed Web of Science ®Google Scholar
• Benjamin SB, Goodman ZD, Ishak KG, Zimmerman HJ, Irey NS. (1985). The morphologic spectrum of halothane-induced hepatic injury: Analysis of 77 cases. Hepatology 5:1163–1171.
   PubMedGoogle Scholar
• Bird GL, Williams R. (1989). Detection of antibodies to a halothane metabolite hapten in sera from patients with halothane-associated hepatitis. J Hepatol 9:366–373.
   PubMedGoogle Scholar
• Boelsterli UA. (2003). Diclofenac-induced liver injury: A paradigm of idiosyncratic drug toxicity. Toxicol Appl Pharmacol. 192:307–322.
   PubMed Web of Science ®Google Scholar
• Boelsterli UA, Lim PL. (2007). Mitochondrial abnormalities—A link to idiosyncratic drug hepatotoxicity? Toxicol Appl Pharmacol 220:92–107.
   PubMed Web of Science ®Google Scholar
• Bottiger LE, Dalen E, Hallen B. (1976). Halothane-induced liver damage: An analysis of the material reported to the Swedish Adverse Drug Reaction Committee, 1966–1973. Acta Anaesthesiol Scand 20:40–46.
   PubMedGoogle Scholar
• Bourdi M, Amouzadeh HR, Rushmore TH, Martin JL, Pohl LR. (2001). Halothane-induced liver injury in outbred guinea pigs: Role of trifluoroacetylated protein adducts in animal susceptibility. Chem Res Toxicol 14:362–370.
   PubMed Web of Science ®Google Scholar
• Bourdi M, Chen W, Peter RM, Martin JL, Buters JT, Nelson SD, Pohl LR. (1996). Human cytochrome P450 2E1 is a major autoantigen associated with halothane hepatitis. Chem Res Toxicol 9:1159–1166.
   PubMed Web of Science ®Google Scholar
• Buchweitz JP, Ganey PE, Bursian SJ, Roth RA. (2002). Underlying endotoxemia augments toxic responses to chlorpromazine: Is there a relationship to drug idiosyncrasy? J Pharmacol Exp Ther 300:460–467..
   PubMed Web of Science ®Google Scholar
• Bunker JP. (1968). Final report of the National Halothane Study. Anesthesiology 29:231–232.
   PubMedGoogle Scholar
• Canalese J, Wyke RJ, Vergani D, Eddleston AL, Williams R. (1981). Circulating immune complexes in patients with fulminant hepatic failure. Gut 22:845–848.
   PubMedGoogle Scholar
• Cheng L, You Q, Yin H, Holt M, Franklin C, Ju C. (2009). Effect of polyI:C cotreatment on halothane-induced liver injury in mice. Hepatology 49:215–226.
   PubMed Web of Science ®Google Scholar
• Chojkier M. (2005). Troglitazone and liver injury: In search of answers. Hepatology 41:237–246.
   PubMed Web of Science ®Google Scholar
• Cosgrove BD, King BM, Hasan MA, Alexopoulos LG, Farazi PA, Hendriks BS, Griffith LG, Sorger PK, Tidor B, Xu JJ, Lauffenburger DA. (2009). Synergistic drug-cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity. Toxicol Appl Pharmacol 237:317–330.
   PubMed Web of Science ®Google Scholar
• Cousins MJ, Plummer JL, Hall PD. (1989). Risk factors for halothane hepatitis. Aust N Z J Surg 59:5–14.
   PubMedGoogle Scholar
• Cribb AE, McQuaid T, Renton KW. (2001). Effect of lipopolysaccharide (LPS)-evoked host defense activation on hepatic microsomal formation and reduction of sulfamethoxazole hydroxylamine in the rat. Biochem Pharmacol 62:457–459.
   PubMedGoogle Scholar
• Daly AK, Aithal GP, Leathart JB, Swainsbury RA, Dang TS, Day CP. (2007). Genetic susceptibility to diclofenac-induced hepatotoxicity: Contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology 132:272–281.
   PubMed Web of Science ®Google Scholar
• Deng X, Stachlewitz RF, Liguori MJ, Blomme EA, Waring JF, Luyendyk JP, Maddox JF, Ganey PE, Roth RA. (2006). Modest inflammation enhances diclofenac hepatotoxicity in rats: Role of neutrophils and bacterial translocation. J Pharmacol Exp Ther 319:1191–1199.
   PubMed Web of Science ®Google Scholar
• Deng X, Luyendyk JP, Zou W, Lu J, Malle E, Ganey PE, Roth RA. (2007). Neutrophil interaction with the hemostatic system contributes to liver injury in rats cotreated with lipopolysaccharide and ranitidine. J Pharmacol Exp Ther 322:852–861.
   PubMedGoogle Scholar
• Deng X, Luyendyk JP, Ganey PE, Roth RA. (2009). Inflammatory stress and idiosyncratic hepatotoxicity: Hints from animal models. Pharmacol Rev 61:262–282.
   PubMed Web of Science ®Google Scholar
• Dieckhaus CM, Thompson CD, Roller SG, Macdonald TL. (2002). Mechanisms of idiosyncratic drug reactions: The case of felbamate. Chem Biol Interact 142:99–117.
   PubMed Web of Science ®Google Scholar
• Dugan CM, MacDonald AE, Roth RA, Ganey PE. (2010). A mouse model of severe halothane hepatitis based on human risk factors. J Pharmacol Exp Ther 333:364–372.
   PubMed Web of Science ®Google Scholar
• Fattinger K, Funk C, Pantze M, Weber C, Reichen J, Stieger B, Meier PJ. (2001). The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: A potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther 69:223–231.
   PubMed Web of Science ®Google Scholar
• Frost L, Mahoney J, Field J, Farrell GC. (1996). Impaired bile flow and disordered hepatic calcium homeostasis are early features of halothane-induced liver injury in guinea pigs. Hepatology 23:80–86.
   PubMedGoogle Scholar
• Fujimoto K, Kumagai K, Ito K, Arakawa S, Ando Y, Oda S, Yamoto T, Manabe S. (2009). Sensitivity of liver injury in heterozygous Sod2 knockout mice treated with troglitazone or acetaminophen. Toxicol Pathol 37:193–200.
   PubMed Web of Science ®Google Scholar
• Fukano M, Amano S, Sato J, Yamamoto K, Adachi H, Okabe H, Fujiyama Y, Bamba T. (2000). Subacute hepatic failure associated with a new antidiabetic agent, troglitazone: A case report with autopsy examination. Hum Pathol 31:250–253.
   PubMed Web of Science ®Google Scholar
• Funk C, Ponelle C, Scheuermann G, Pantze M. (2001). Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: In vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat. Mol Pharmacol 59:627–635.
   PubMed Web of Science ®Google Scholar
• Funk C, Pantze M, Jehle L, Ponelle C, Scheuermann G, Lazendic M, Gasser R. (2001). Troglitazone-induced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male and female rats. Correlation with the gender difference in troglitazone sulfate formation and the inhibition of the canalicular bile salt export pump (Bsep) by troglitazone and troglitazone sulfate. Toxicology 167:83–98.
   PubMed Web of Science ®Google Scholar
• Ganey PE, Roth RA. (2001). Concurrent inflammation as a determinant of susceptibility to toxicity from xenobiotic agents. Toxicology 169:195–208.
   PubMed Web of Science ®Google Scholar
• Ganey PE, Luyendyk JP, Maddox JF, Roth RA. (2004). Adverse hepatic drug reactions: Inflammatory episodes as consequence and contributor. Chem Biol Interact 150:35–51.
   PubMed Web of Science ®Google Scholar
• Gregus Z. (2008). Mechanisms of toxicity. In: Klaassen CD, ed. Casarett & Doull’s Toxicology, The Basic Science of Poisons. 7th ed. New York: McGraw Hill Medical, 45–106.
   Google Scholar
• Grillo MP, Knutson CG, Sanders PE, Waldon DJ, Hua F, Ware JA. (2003). Studies on the chemical reactivity of diclofenac acyl glucuronide with glutathione: Identification of diclofenac-S-acyl-glutathione in rat bile. Drug Metab Dispos 31:1327–1336.
   PubMed Web of Science ®Google Scholar
• Grillo MP, Ma J, Teffera Y, Waldon DJ. (2008). A novel bioactivation pathway for 2-[2-(2,6-dichlorophenyl)aminophenyl]ethanoic acid (diclofenac) initiated by cytochrome P450-mediated oxidative decarboxylation. Drug Metab Dispos 36:1740–1744.
   PubMed Web of Science ®Google Scholar
• Hall DB, Macgregor TR. (2007). Case-control exploration of relationships between early rash or liver toxicity and plasma concentrations of nevirapine and primary metabolites. HIV Clin Trials 8:391–399.
   PubMed Web of Science ®Google Scholar
• Han D, Hanawa N, Saberi B, Kaplowitz N. (2006). Mechanisms of liver injury. III. Role of glutathione redox status in liver injury. Am J Physiol Gastrointest Liver Physiol 291:G1–G7
   PubMed Web of Science ®Google Scholar
• Harrill AH, Watkins PB, Su S, Ross PK, Harbourt DE, Stylianou IM, Boorman GA, Russo MW, Sackler RS, Harris SC, Smith PC, Tennant R, Bogue M, Paigen K, Harris C, Contractor T, Wiltshire T, Rusyn I, Threadgill DW. (2009). Mouse population-guided resequencing reveals that variants in CD44 contribute to acetaminophen-induced liver injury in humans. Genome Res 19:1507–1515.
   PubMed Web of Science ®Google Scholar
• Helvering LM, Richardson KA, Englehardt JA, Richardson FC. (1995). Fialuridine (FIAU) depletes mitochondrial DNA in the liver and heart of rat, dog and monkey during long-term oral administration [abstract]. Am Assoc Cancer Res 36:358.
   Google Scholar
• Hijona E, Hijona L, Arenas JI, Bujanda L. (2010). Inflammatory mediators of hepatic steatosis. Mediators Inflamm 2010:837419.
   PubMedGoogle Scholar
• Hofmann AF. (1989). Current concepts of biliary secretion. Dig Dis Sci 34:16S–S20
   PubMedGoogle Scholar
• Hsiao CJ, Younis H, Boelsterli UA. (2010). Trovafloxacin, a fluoroquinolone antibiotic with hepatotoxic potential, causes mitochondrial peroxynitrite stress in a mouse model of underlying mitochondrial dysfunction. Chem Biol Interact 188:204–213.
   PubMed Web of Science ®Google Scholar
• Ishak KG, Irey NS. (1972). Hepatic injury associated with the phenothiazines. Clinicopathologic and follow-up study of 36 patients. Arch Pathol 93:283–304.
   PubMedGoogle Scholar
• Jewell H, Maggs JL, Harrison AC, O’Neill PM, Ruscoe JE, Park BK. (1995). Role of hepatic metabolism in the bioactivation and detoxication of amodiaquine. Xenobiotica 25:199–217.
   PubMed Web of Science ®Google Scholar
• Jin R, Yang G, Li G. (2010). Inflammatory mechanisms in ischemic stroke: Role of inflammatory cells. J Leukoc Biol 87:779–789.
   PubMed Web of Science ®Google Scholar
• Kaplowitz N. (2005). Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 4:489–499.
   PubMed Web of Science ®Google Scholar
• Kashimshetty R, Desai VG, Kale VM, Lee T, Moland CL, Branham WS, New LS, Chan EC, Younis H, Boelsterli UA. (2009). Underlying mitochondrial dysfunction triggers flutamide-induced oxidative liver injury in a mouse model of idiosyncratic drug toxicity. Toxicol Appl Pharmacol 238:150–159.
   PubMed Web of Science ®Google Scholar
• Khouri MR, Saul SH, Dlugosz AA, Soloway RD. (1987). Hepatocanalicular injury associated with vitamin A derivative etretinate. An idiosyncratic hypersensitivity reaction. Dig Dis Sci 32:1207–1211.
   PubMedGoogle Scholar
• Kleiner DE, Gaffey MJ, Sallie R, Tsokos M, Nichols L, McKenzie R, Straus SE, Hoofnagle JH. (1997). Histopathologic changes associated with fialuridine hepatotoxicity. Mod Pathol 10:192–199.
   PubMed Web of Science ®Google Scholar
• Knapp AC, Todesco L, Beier K, Terracciano L, Sagesser H, Reichen J, Krahenbuhl S. (2008). Toxicity of valproic acid in mice with decreased plasma and tissue carnitine stores. J Pharmacol Exp Ther 324:568–575.
   PubMed Web of Science ®Google Scholar
• Kostrubsky SE, Strom SC, Kalgutkar AS, Kulkarni S, Atherton J, Mireles R, Feng B, Kubik R, Hanson J, Urda E, Mutlib AE. (2006). Inhibition of hepatobiliary transport as a predictive method for clinical hepatotoxicity of nefazodone. Toxicol Sci 90:451–459.
   PubMed Web of Science ®Google Scholar
• Labbe G, Pessayre D, Fromenty B. (2008). Drug-induced liver injury through mitochondrial dysfunction: Mechanisms and detection during preclinical safety studies. Fundam Clin Pharmacol 22:335–353.
   PubMed Web of Science ®Google Scholar
• Lee YH, Chung MC, Lin Q, Boelsterli UA. (2008). Troglitazone-induced hepatic mitochondrial proteome expression dynamics in heterozygous Sod2(+/−) mice: Two-stage oxidative injury. Toxicol Appl Pharmacol 231:43–51.
   PubMed Web of Science ®Google Scholar
• Lewis W, Griniuviene B, Tankersley KO, Levine ES, Montione R, Engelman L, de Court Ascenzi MA, Hornbuckle WE, Gerin JL, Tennant BC. (1997). Depletion of mitochondrial DNA, destruction of mitochondria and accumulation of lipid droplets result from fialuridine treatment in woodchucks (Marmota monax). Lab Invest 76:77–87.
   PubMed Web of Science ®Google Scholar
• Lheureux PE, Hantson P. (2009). Carnitine in the treatment of valproic acid-induced toxicity. Clin Toxicol (Phila) 47:101–111.
   PubMed Web of Science ®Google Scholar
• Li AP. (2002). A review of the common properties of drugs with idiosyncratic hepatotoxicity and the “multiple determinant hypothesis” for the manifestation of idiosyncratic drug toxicity. Chem Biol Interact 142:7–23.
   PubMed Web of Science ®Google Scholar
• Lim PL, Liu J, Go ML, Boelsterli UA. (2008). The mitochondrial superoxide/thioredoxin-2/Ask1 signaling pathway is critically involved in troglitazone-induced cell injury to human hepatocytes. Toxicol Sci 101:341–349.
   PubMed Web of Science ®Google Scholar
• Lind RC, Gandolfi AJ, Hall PD. (1992a). Subanesthetic halothane is hepatotoxic in the guinea pig. Anesth Analg 74:559–563.
   PubMedGoogle Scholar
• Lind RC, Gandolfi AJ, Hall PM. (1992b). Glutathione depletion enhances subanesthetic halothane hepatotoxicity in guinea pigs. Anesthesiology 77:721–727.
   PubMedGoogle Scholar
• Lind RC, Gandolfi AJ, Hall PM. (1994). A model for fatal halothane hepatitis in the guinea pig. Anesthesiology 81:478–487.
   PubMed Web of Science ®Google Scholar
• Lind RC, Gandolfi AJ. (1997). Late dimethyl sulfoxide administration provides a protective action against chemically induced injury in both the liver and the kidney. Toxicol Appl Pharmacol 142:201–207.
   PubMed Web of Science ®Google Scholar
• Lu J, Roth RA, Ganey PE. (2009). Amiodarone exposure during modest inflammation induces idiosyncrasy-like liver injury in rats. Toxicologist 102(S-1):452.
   Google Scholar
• Lucena MI, Andrade RJ, Martinez C, Ulzurrun E, Garcia-Martin E, Borraz Y, Fernandez MC, Romero-Gomez M, Castiella A, Planas R, Costa J, Anzola S, Agundez JA. (2008). Glutathione S-transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury. Hepatology 48:588–596.
   PubMed Web of Science ®Google Scholar
• Luyendyk JP, Maddox JF, Cosma GN, Ganey PE, Cockerell GL, Roth RA. (2003). Ranitidine treatment during a modest inflammatory response precipitates idiosyncrasy-like liver injury in rats. J Pharmacol Exp Ther 307:9–16.
   PubMed Web of Science ®Google Scholar
• Luyendyk JP, Maddox JF, Green CD, Ganey PE, Roth RA. (2004). Role of hepatic fibrin in idiosyncrasy-like liver injury from lipopolysaccharide-ranitidine coexposure in rats. Hepatology 40:1342–1351.
   PubMed Web of Science ®Google Scholar
• Luyendyk JP, Shaw PJ, Green CD, Maddox JF, Ganey PE, Roth RA. (2005). Coagulation-mediated hypoxia and neutrophil-dependent hepatic injury in rats given lipopolysaccharide and ranitidine. J Pharmacol Exp Ther 314:1023–1031.
   PubMed Web of Science ®Google Scholar
• Luyendyk JP, Lehman-McKeeman LD, Nelson DM, Bhaskaran VM, Reilly TP, Car B. D, Cantor GH, Deng X, Maddox JF, Ganey PE, Roth RA. (2006). Coagulation-dependent gene expression and liver injury in rats given lipopolysaccharide with ranitidine but not with famotidine. J Pharmacol Exp Ther 317:635–643.
   PubMed Web of Science ®Google Scholar
• Mancy A, Antignac M, Minoletti C, Dijols S, Mouries V, Duong NT, Battioni P, Dansette PM, Mansuy D. (1999). Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: Particular efficiency and regioselectivity of P450 2Cs. Biochemistry 38:14264–14270.
   PubMed Web of Science ®Google Scholar
• Marion TL, Leslie EM, Brouwer KL. (2007). Use of sandwich-cultured hepatocytes to evaluate impaired bile acid transport as a mechanism of drug-induced hepatotoxicity. Mol Pharm 4:911–918.
   PubMed Web of Science ®Google Scholar
• Masubuchi Y (2006). Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: A review. Drug Metab Pharmacokinet 5:347–356.
   Google Scholar
• Mathieu A, Dipadua D, Kahan B. D, Galdabini JJ, Mills J. (1975). Correlation between specific immunity to a metabolite of halothane and hepatic lesions after multiple exposures. Anesth Analg 54:332–339.
   PubMedGoogle Scholar
• McKenzie R, Fried MW, Sallie R, Conjeevaram H, Di Bisceglie AM, Park Y, Savarese B, Kleiner D, Tsokos M, Luciano C. (1995). Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med 333:1099–1105.
   PubMed Web of Science ®Google Scholar
• Mehendale HM. (2005). Tissue repair: An important determinant of final outcome of toxicant-induced injury. Toxicol Pathol 33:41–51.
   PubMed Web of Science ®Google Scholar
• Miyamoto G, Zahid N, Uetrecht JP. (1997). Oxidation of diclofenac to reactive intermediates by neutrophils, myeloperoxidase, and hypochlorous acid. Chem Res Toxicol 10:414–419.
   PubMed Web of Science ®Google Scholar
• Morita M, Akai S, Hosomi H, Tsuneyama K, Nakajima M, Yokoi T. (2009). Drug-induced hepatotoxicity test using gamma-glutamylcysteine synthetase knockdown rat. Toxicol Lett 189:159–165.
   PubMed Web of Science ®Google Scholar
• Murphy EJ, Davern TJ, Shakil AO, Shick L, Masharani U, Chow H, Freise C, Lee WM, Bass NM. (2000). Troglitazone-induced fulminant hepatic failure. Acute Liver Failure Study Group. Dig Dis Sci 45:549–553.
   PubMed Web of Science ®Google Scholar
• Mushin WW, Rosen M, Jones EV. (1971). Post-halothane jaundice in relation to previous administration of halothane. BMJ 3:18–22.
   PubMedGoogle Scholar
• Nakayama S, Atsumi R, Takakusa H, Kobayashi Y, Kurihara A, Nagai Y, Nakai D, Okazaki O. (2009). A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding. Drug Metab Dispos 37:1970–1977.
   PubMed Web of Science ®Google Scholar
• Nassar AE, Lopez-Anaya A. (2004). Strategies for dealing with reactive intermediates in drug discovery and development. Curr Opin Drug Discov Dev 7:126–136.
   PubMed Web of Science ®Google Scholar
• Neuberger JM, Kenna JG, Williams R. (1987). Halothane hepatitis: Attempt to develop an animal model. Int J Immunopharmacol 9:123–131.
   PubMedGoogle Scholar
• Ong MM, Wang AS, Leow KY, Khoo YM, Boelsterli UA. (2006). Nimesulide-induced hepatic mitochondrial injury in heterozygous Sod2(+/−) mice. Free Radic Biol Med 40:420–429.
   PubMed Web of Science ®Google Scholar
• Ong MM, Latchoumycandane C, Boelsterli UA. (2007). Troglitazone-induced hepatic necrosis in an animal model of silent genetic mitochondrial abnormalities. Toxicol Sci 97:205–213.
   PubMed Web of Science ®Google Scholar
• Park BK, Kitteringham NR, Maggs JL, Pirmohamed M, Williams DP. (2005). The role of metabolic activation in drug-induced hepatotoxicity. Annu Rev Pharmacol Toxicol 45:177–202.
   PubMed Web of Science ®Google Scholar
• Pessayre D, Fromenty B, Mansouri A, Berson A. (2003). Hepatotoxicity due to mitochondrial injury. In: Kaplowitz N, DeLeve LD, eds. Drug-Induced Liver Disease. New York: Marcel Dekker, 55–83.
   Google Scholar
• Petersen KU. (2002). From toxic precursors to safe drugs. Mechanisms and relevance of idiosyncratic drug reactions. Arzneimittelforschung 52:423–429.
   PubMedGoogle Scholar
• Plummer JL, Hall PD, Jenner MA, Cousins MJ. (1987). Hepatic effects of repeated halothane anesthetics in the hypoxic rat model. Anesthesiology 67:355–360.
   PubMedGoogle Scholar
• Popovic M, Caswell JL, Mannargudi B, Shenton JM, Uetrecht JP. (2006). Study of the sequence of events involved in nevirapine-induced skin rash in Brown Norway rats. Chem Res Toxicol 19:1205–1214.
   PubMed Web of Science ®Google Scholar
• Rana SV, Pal R, Vaiphie K, Singh K. (2006). Effect of different oral doses of isoniazid-rifampicin in rats. Mol Cell Biochem 289:39–47.
   PubMedGoogle Scholar
• Richardson FC, Engelhardt JA, Bowsher RR. (1994). Fialuridine accumulates in DNA of dogs, monkeys, and rats following long-term oral administration. Proc Natl Acad Sci U S A 91:12003–12007.
   PubMedGoogle Scholar
• Richardson FC, Tennant BC, Meyer DJ, Richardson KA, Mann PC, McGinty GR, Wolf JL, Zack PM, Bendele RA. (1999). An evaluation of the toxicities of 2′-fluorouridine and 2′-fluorocytidine-HCl in F344 rats and woodchucks (Marmota monax). Toxicol Pathol 27:607–617.
   PubMedGoogle Scholar
• Roth RA, Harkema JR, Pestka JP, Ganey PE. (1997). Is exposure to bacterial endotoxin a determinant of susceptibility to intoxication from xenobiotic agents? Toxicol Appl Pharmacol 147:300–311.
   PubMed Web of Science ®Google Scholar
• Roth RA, Ganey PE. (2010). Intrinsic versus idiosyncratic drug-induced hepatotoxicity—Two villains or one? J Pharmacol Exp Ther 332:692–697.
   PubMed Web of Science ®Google Scholar
• Sallie R, Kleiner D, Richardson F, Conjeevaram H, Zullo S, Mutimer D, Hoover S. (1994). Mechanisms of FIAU induced hepatotoxicity [abstract]. Hepatology 20:209A.
   Google Scholar
• Sallustio BC, Sabordo L, Evans AM, Nation RL. (2000). Hepatic disposition of electrophilic acyl glucuronide conjugates. Curr Drug Metab 1:163–80.
   PubMed Web of Science ®Google Scholar
• Santos NA, Medina WS, Martins NM, Mingatto FE, Curti C, Santos AC. (2008). Aromatic antiepileptic drugs and mitochondrial toxicity: Effects on mitochondria isolated from rat liver. Toxicol In Vitro 22:1143–1152.
   PubMed Web of Science ®Google Scholar
• Seitz S, Kretz-Rommel A, Oude Elferink RP, Boelsterli UA. (1998). Selective protein adduct formation of diclofenac glucuronide is critically dependent on the rat canalicular conjugate export pump (Mrp2). Chem Res Toxicol 11:513–519.
   PubMed Web of Science ®Google Scholar
• Senior JR. (2008). What is idiosyncratic hepatotoxicity? What is it not? Hepatology 47:1813–1815.
   PubMed Web of Science ®Google Scholar
• Shaw PJ, Hopfensperger MJ, Ganey PE, Roth RA. (2007). Lipopolysaccharide and trovafloxacin coexposure in mice causes idiosyncrasy-like liver injury dependent on tumor necrosis factor-alpha. Toxicol Sci 100:259–266.
   PubMed Web of Science ®Google Scholar
• Shaw PJ, Beggs KM, Sparkenbaugh EM, Dugan CM, Ganey PE, Roth RA. (2009a). Trovafloxacin enhances TNF-induced inflammatory stress and cell death signaling and reduces TNF clearance in a murine model of idiosyncratic hepatotoxicity. Toxicol Sci 111:288–301.
   PubMed Web of Science ®Google Scholar
• Shaw PJ, Ditewig AC, Waring JF, Liguori MJ, Blomme EA, Ganey PE, Roth RA. (2009b). Coexposure of mice to trovafloxacin and lipopolysaccharide, a model of idiosyncratic hepatotoxicity, results in a unique gene expression profile and interferon gamma-dependent liver injury. Toxicol Sci 107:270–280.
   PubMed Web of Science ®Google Scholar
• Shaw PJ, Fullerton AM, Scott MA, Ganey PE, Roth RA. (2009c). The role of the hemostatic system in murine liver injury induced by coexposure to lipopolysaccharide and trovafloxacin, a drug with idiosyncratic liability. Toxicol Appl Pharmacol 236:293–300.
   PubMed Web of Science ®Google Scholar
• Shaw PJ, Ganey PE, Roth RA. (2009d). Tumor necrosis factor alpha is a proximal mediator of synergistic hepatotoxicity from trovafloxacin/lipopolysaccharide coexposure. J Pharmacol Exp Ther 328:62–68.
   PubMed Web of Science ®Google Scholar
• Shaw PJ, Ganey PE, Roth RA. (2009e). Trovafloxacin enhances the inflammatory response to a Gram-negative or a Gram-positive bacterial stimulus resulting in neutrophil-dependent liver injury in mice. J Pharmacol Exp Ther 330:72–78.
   PubMed Web of Science ®Google Scholar
• Shaw PJ, Ganey PE, Roth RA. (2010). Idiosyncratic, drug-induced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicity. Toxicol Sci 118:7–18.
   PubMed Web of Science ®Google Scholar
• Shenton JM, Chen J, Uetrecht JP. (2004). Animal models of idiosyncratic drug reactions. Chem Biol Interact 150:53–70.
   PubMed Web of Science ®Google Scholar
• Shin NY, Liu Q, Stamer SL, Liebler DC. (2007). Protein targets of reactive electrophiles in human liver microsomes. Chem Res Toxicol 20:859–867.
   PubMed Web of Science ®Google Scholar
• Stevenson W, Gaffey M, Ishitani M, McCullough C, Dickson R, Caldwell S, Lobo P, Pruett T. (1995). Clinical course of four patients receiving the experimental antiviral agent fialuridine for the treatment of chronic hepatitis B infection. Transplant Proc 27:1219–1221.
   PubMedGoogle Scholar
• Takakusa H, Masumoto H, Yukinaga H, Makino C, Nakayama S, Okazaki O, Sudo K. (2008). Covalent binding and tissue distribution/retention assessment of drugs associated with idiosyncratic drug toxicity. Drug Metab Dispos 36:1770–1779.
   PubMed Web of Science ®Google Scholar
• Takeuchi O, Akira S. (2010). Pattern recognition receptors and inflammation. Cell 140:805–820.
   PubMed Web of Science ®Google Scholar
• Tang W. (2003). The metabolism of diclofenac—Enzymology and toxicology perspectives. Curr Drug Metab 4:319–329.
   PubMed Web of Science ®Google Scholar
• Tang W. (2007). Drug metabolite profiling and elucidation of drug-induced hepatotoxicity. Expert Opin Drug Metab Toxicol 3:407–420.
   PubMed Web of Science ®Google Scholar
• Tasduq SA, Kaiser P, Sharma SC, Johri RK. (2007). Potentiation of isoniazid-induced liver toxicity by rifampicin in a combinational therapy of antitubercular drugs (rifampicin, isoniazid and pyrazinamide) in Wistar rats: A toxicity profile study. Hepatol Res 37:845–853.
   PubMed Web of Science ®Google Scholar
• Tay VK, Wang AS, Leow KY, Ong MM, Wong KP, Boelsterli UA. (2005). Mitochondrial permeability transition as a source of superoxide anion induced by the nitroaromatic drug nimesulide in vitro. Free Radic Biol Med 39:949–959.
   PubMed Web of Science ®Google Scholar
• Tennant BC, Baldwin BH, Graham LA, Ascenzi MA, Hornbuckle WE, Rowland PH, Tochkov IA, Yeager AE, Erb HN, Colacino JM, Lopez C, Engelhardt JA, Bowsher RR, Richardson FC, Lewis W, Cote PJ, Korba BE, Gerin JL. (1998). Antiviral activity and toxicity of fialuridine in the woodchuck model of hepatitis B virus infection. Hepatology 28:179–191.
   PubMed Web of Science ®Google Scholar
• Tukov FF, Maddox JF, Amacher DE, Bobrowski WF, Roth RA, Ganey PE. (2006). Modeling inflammation-drug interactions in vitro: A rat Kupffer cell-hepatocyte coculture system. Toxicol In Vitro 20:1488–1499.
   PubMed Web of Science ®Google Scholar
• Tukov FF, Luyendyk JP, Ganey PE, Roth RA. (2007). The role of tumor necrosis factor alpha in lipopolysaccharide/ranitidine-induced inflammatory liver injury. Toxicol Sci 100:267–280.
   PubMed Web of Science ®Google Scholar
• Uetrecht J. (1991). Metabolism of drugs by activated leukocytes: Implications for drug-induced lupus and other drug hypersensitivity reactions. Adv Exp Med Biol 283:121–132.
   PubMedGoogle Scholar
• Uetrecht J. (2007). Idiosyncratic drug reactions: Current understanding. Annu Rev Pharmacol Toxicol 47:513–539.
   PubMed Web of Science ®Google Scholar
• Uetrecht J. (2008). Idiosyncratic drug reactions: Past, present, and future. Chem Res Toxicol 21:84–92.
   PubMed Web of Science ®Google Scholar
• Ulrich RG. (2007). Idiosyncratic toxicity: A convergence of risk factors. Annu Rev Med 58:17–34.
   PubMed Web of Science ®Google Scholar
• Ulrich RG, Bacon JA, Branstetter DG, Cramer CT, Funk GM, Hunt CE, Petrella DK, Sun EL. (1995). Induction of a hepatic toxic syndrome in the Dutch-belted rabbit by a quinoxalinone anxiolytic. Toxicology 98:187–198.
   PubMed Web of Science ®Google Scholar
• Ulrich RG, Bacon JA, Cramer CT, Petrella DK, Sun EL, Meglasson MD, Holmuhamedov E. (1998). Disruption of mitochondrial activities in rabbit and human hepatocytes by a quinoxalinone anxiolytic and its carboxylic acid metabolite. Toxicology 131:33–47.
   PubMedGoogle Scholar
• Ulrich RG, Bacon JA, Brass EP, Cramer CT, Petrella DK, Sun EL. (2001). Metabolic, idiosyncratic toxicity of drugs: Overview of the hepatic toxicity induced by the anxiolytic, panadiplon. Chem Biol Interact 134:251–270.
   PubMed Web of Science ®Google Scholar
• Wang EJ, Casciano CN, Clement RP, Johnson WW. (2003). Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: Evidence for contingent unequal binding sites. Pharm Res 20:537–544.
   PubMed Web of Science ®Google Scholar
• Waring JF, Anderson MG. (2005). Idiosyncratic toxicity: Mechanistic insights gained from analysis of prior compounds. Curr Opin Drug Discov Dev 8:59–65.
   PubMed Web of Science ®Google Scholar
• Waring JF, Liguori MJ, Luyendyk JP, Maddox JF, Ganey PE, Stachlewitz RF, North C, Blomme EA, Roth RA. (2006). Microarray analysis of lipopolysaccharide potentiation of trovafloxacin-induced liver injury in rats suggests a role for proinflammatory chemokines and neutrophils. J Pharmacol Exp Ther 316:1080–1087.
   PubMed Web of Science ®Google Scholar
• Watkins PB. (1990). Role of cytochromes P450 in drug metabolism and hepatotoxicity. Semin Liver Dis 10:235–250.
   PubMed Web of Science ®Google Scholar
• Watkins PB. (2005). Idiosyncratic liver injury: Challenges and approaches. Toxicol Pathol 33:1–5.
   PubMed Web of Science ®Google Scholar
• Watkins PB, Kaplowitz N, Slattery JT, Colonese CR, Colucci SV, Stewart PW, Harris SC. (2006). Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: A randomized controlled trial. JAMA 296:87–93.
   PubMed Web of Science ®Google Scholar
• Wen B, Coe KJ, Rademacher P, Fitch WL, Monshouwer M, Nelson SD. (2008). Comparison of in vitro bioactivation of flutamide and its cyano analogue: Evidence for reductive activation by human NADPH:Cytochrome P450 reductase. Chem Res Toxicol 21:2393–406.
   PubMed Web of Science ®Google Scholar
• Wen B, Chen Y, Fitch WL. (2009). Metabolic activation of nevirapine in human liver microsomes: Dehydrogenation and inactivation of cytochrome P450 3A4. Drug Metab Dispos 37:1557–1562.
   PubMed Web of Science ®Google Scholar
• Xu JJ, Henstock PV, Dunn MC, Smith AR, Chabot JR, de Graaf D. (2008). Cellular imaging predictions of clinical drug-induced liver injury. Toxicol Sci 105:97–105.
   PubMed Web of Science ®Google Scholar
• You Q, Cheng, L, Reilly T. P. Wegmann, D, Ju C. (2006). Role of neutrophils in a mouse model of halothane-induced liver injury. Hepatology 44:1421–1431.
   PubMed Web of Science ®Google Scholar
• Zhou S. (2003). Separation and detection methods for covalent drug-protein adducts. J Chromatogr B Analyt Technol Biomed Life Sci 797:63–90.
   PubMed Web of Science ®Google Scholar
• Zou W, Beggs KM, Sparkenbaugh EM, Jones AD, Younis HS, Roth RA, Ganey PE. (2009a). Sulindac metabolism and synergy with tumor necrosis factor-alpha in a drug-inflammation interaction model of idiosyncratic liver injury. J Pharmacol Exp Ther 331:114–121.
   PubMed Web of Science ®Google Scholar
• Zou W, Devi SS, Sparkenbaugh E, Younis HS, Roth RA, Ganey PE. (2009b). Hepatotoxic interaction of sulindac with lipopolysaccharide: Role of the hemostatic system. Toxicol Sci 108:184–193.
   PubMed Web of Science ®Google Scholar